Analytical validation of the PanTracer™ LBx assay Read more about Analytical validation of the PanTracer™ LBx assay
Validation of NEO │ PanTracer LBx, a liquid biopsy precision oncology pan-solid tumor comprehensive genomic profiling assay (CGP) Read more about Validation of NEO │ PanTracer LBx, a liquid biopsy precision oncology pan-solid tumor comprehensive genomic profiling assay (CGP)
Non-invasive identification of actionable biomarkers in advanced solid tumors by comprehensive genomic profiling with NEO | PanTracer LBx assay Read more about Non-invasive identification of actionable biomarkers in advanced solid tumors by comprehensive genomic profiling with NEO | PanTracer LBx assay
Analytical validation of PanTracer LBx performance, a comprehensive pan-solid tumor liquid biopsy assay Read more about Analytical validation of PanTracer LBx performance, a comprehensive pan-solid tumor liquid biopsy assay
Exploitation of treatment induced tumor lysis to enhance sensitivity of ctDNA analysis: A first-in-human pilot study Read more about Exploitation of treatment induced tumor lysis to enhance sensitivity of ctDNA analysis: A first-in-human pilot study
Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC) Read more about Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC)
ctDNA detection in early-stage non-small cell lung cancer Read more about ctDNA detection in early-stage non-small cell lung cancer
Clinical utility of TP53 mutations (TP53m) dynamic monitoring in circulating tumor DNA (ctDNA) in patients (pts) with high-grade ovarian carcinomas (HGOC) Read more about Clinical utility of TP53 mutations (TP53m) dynamic monitoring in circulating tumor DNA (ctDNA) in patients (pts) with high-grade ovarian carcinomas (HGOC)
Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer Read more about Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer
Circulating tumor DNA (ctDNA) clearance as a biomarker in patients with locally advanced NSCLC following chemoradiation Read more about Circulating tumor DNA (ctDNA) clearance as a biomarker in patients with locally advanced NSCLC following chemoradiation